Abby Bronson
About Abby Bronson
Abby Bronson: Head of Patient Advocacy & External Innovation
Abby Bronson serves as the Head of Patient Advocacy & External Innovation. In her role, Abby focuses on advocating for patients and driving forward external innovations in the field of muscular dystrophies. Her work aims to bridge the gap between scientific research and patient needs through educational initiatives and partnerships with neuromuscular organizations. Abby plays a critical role in ensuring that new developments in the treatment of rare muscle disorders are aligned with patient interests and that there is robust support for those affected.
Research Focus on Muscle-Targeted Therapies
Abby Bronson is devoted to developing novel muscle-targeted therapies to treat various muscular dystrophies, such as Duchenne, Becker, Limb-Girdle, and McArdle disease. Her work utilizes a proprietary drug discovery platform designed to assess integrated muscle function in whole organ extracts. This platform helps identify small molecule precision medicines that regulate essential proteins in muscle tissue, aiming to provide effective treatments for these debilitating conditions.
Advancing EDG-5506 for Muscular Dystrophies
One of Abby Bronson's key projects involves the clinical development of EDG-5506, a therapeutic candidate targeting fast skeletal muscle fibers for the treatment of muscular dystrophies. This molecule is currently undergoing clinical trials to assess its safety, efficacy, and pharmacokinetics in relevant patient populations. The goal is to provide a targeted treatment that can improve muscle function and quality of life for individuals with these conditions.
Development of EDG-7500 for Cardiac Conditions
In addition to her work on muscular dystrophies, Abby Bronson is also involved in the development of EDG-7500, a first-in-class oral, selective cardiac sarcomere modulator. This medication is being developed to treat hypertrophic cardiomyopathy and other conditions associated with cardiac diastolic dysfunction. Clinical trials are being conducted to evaluate its safety, efficacy, and pharmacokinetics, with the aim of addressing unmet needs in cardiac care.
Educational and Advocacy Efforts
Abby Bronson is actively engaged in educational and advocacy initiatives to support individuals with rare muscle disorders. She works to raise awareness through community newsletters and partnerships with various neuromuscular organizations. These efforts help to disseminate vital information, provide support networks, and advocate for increased research and resources dedicated to these rare conditions.